What is NIKI BIOSOLUTIONS INC,'s earnings per share (EPS)?

NIKI BIOSOLUTIONS INC, (NIKI) reported diluted earnings per share of $-0.19 for fiscal year 2025. This represents a 75.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NIKI BIOSOLUTIONS INC, Financials

NIKI

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE December

This page shows NIKI BIOSOLUTIONS INC, (NIKI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating NIKI BIOSOLUTIONS INC,'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

2/5

NIKI BIOSOLUTIONS INC, passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 1 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.35x

For every $1 of reported earnings, NIKI BIOSOLUTIONS INC, generates $1.35 in operating cash flow (-$1.8M OCF vs -$1.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$1.4M

YoY+68.1%

NIKI BIOSOLUTIONS INC, reported -$1.4M in net income in fiscal year 2025. This represents an increase of 68.1% from the prior year.

EPS (Diluted)

$-0.19

YoY+75.6%

NIKI BIOSOLUTIONS INC, earned $-0.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 75.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3.5M

YoY+295.0%

5Y CAGR-1.0%

NIKI BIOSOLUTIONS INC, held $3.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-5.9%

YoY+14.3pp

5Y CAGR-17.7pp

NIKI BIOSOLUTIONS INC,'s ROE was -5.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 14.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$353K

YoY-83.9%

5Y CAGR-50.3%

NIKI BIOSOLUTIONS INC, invested $353K in research and development in fiscal year 2025. This represents a decrease of 83.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

NIKI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	$431K-66.7%	$1.3M-15.9%	$1.5M	N/A
Cost of Revenue	N/A	N/A	$421K-65.4%	$1.2M-16.7%	$1.5M	N/A
Gross Profit	N/A	N/A	$11K-86.8%	$80K-2.2%	$82K	N/A
R&D Expenses	$353K-83.9%	$2.2M-57.8%	$5.2M-43.6%	$9.2M-15.2%	$10.9M-6.2%	$11.6M
SG&A Expenses	$573K-14.4%	$669K-65.3%	$1.9M-63.0%	$5.2M-3.5%	$5.4M+11.5%	$4.9M
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$1.4M+68.1%	-$4.3M-51.1%	-$2.8M+71.2%	-$9.8M+60.9%	-$25.0M-609.1%	$4.9M
EPS (Diluted)	$-0.19+75.6%	$-0.78-25.8%	$-0.62+77.5%	$-2.75+61.5%	$-7.15-457.5%	$2.00

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q2'24	Q4'23	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NIKI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$18.7M+15.9%	$16.1M-21.9%	$20.6M-1.1%	$20.9M-4.7%	$21.9M-50.5%	$44.2M
Current Assets	$3.6M+274.4%	$960K-61.2%	$2.5M-65.0%	$7.1M-44.3%	$12.7M-62.3%	$33.7M
Cash & Equivalents	$3.5M+295.0%	$874K-56.4%	$2.0M-60.0%	$5.0M-39.3%	$8.3M+127.9%	$3.6M
Inventory	N/A	N/A	N/A	$28K-22.5%	$36K-8.6%	$39K
Accounts Receivable	N/A	N/A	$48K-72.6%	$174K+121.6%	$79K+26.5%	$62K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	-$4.4M+11.6%	-$5.0M-19.0%	-$4.2M-181.6%	$5.2M+403.2%	-$1.7M-128.0%	$6.1M
Current Liabilities	$4.6M+5.9%	$4.3M+106.7%	$2.1M	N/A	$4.4M+13.1%	$3.9M
Long-Term Debt	N/A	N/A	N/A	$130K-56.2%	$296K0.0%	$296K
Total Equity	$23.1M+9.4%	$21.1M-14.9%	$24.8M+58.1%	$15.7M-33.4%	$23.6M-43.6%	$41.8M
Retained Earnings	-$73.8M-1.9%	-$72.4M-6.3%	-$68.2M-4.3%	-$65.3M-17.6%	-$55.5M-82.2%	-$30.5M

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q2'24	Q4'23	Q2'23
Total Assets	$18.7M+6.3%	$17.6M-2.9%	$18.1M+12.2%	$16.1M	N/A	$17.7M-14.2%	$20.6M+43.2%	$14.4M
Current Assets	$3.6M+44.9%	$2.5M-17.5%	$3.0M+213.2%	$960K	N/A	$1.5M-38.0%	$2.5M+30.5%	$1.9M
Cash & Equivalents	$3.5M+51.9%	$2.3M-17.6%	$2.8M+215.3%	$874K+15.9%	$755K-3.6%	$783K-61.0%	$2.0M+489.3%	$340K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$22K-54.3%	$48K-28.1%	$66K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	-$4.4M+10.7%	-$5.0M+1.5%	-$5.0M-0.5%	-$5.0M	N/A	-$5.0M-17.7%	-$4.2M+43.4%	-$7.4M
Current Liabilities	$4.6M+4.0%	$4.4M+338.4%	$1.0M-76.8%	$4.3M	N/A	$1.3M-37.3%	$2.1M+46.4%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$23.1M+2.6%	$22.5M-2.6%	$23.1M+9.5%	$21.1M+68.9%	$12.5M-44.8%	$22.7M-8.8%	$24.8M+13.7%	$21.8M
Retained Earnings	-$73.8M-0.4%	-$73.5M-0.8%	-$72.9M-0.6%	-$72.4M	N/A	-$70.8M-3.9%	-$68.2M+3.8%	-$70.8M

NIKI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M-54.4%	-$1.2M+84.6%	-$7.7M+37.3%	-$12.3M+15.9%	-$14.7M+8.0%	-$15.9M
Capital Expenditures	N/A	N/A	$3K-98.4%	$187K+41.9%	$132K-18.3%	$161K
Free Cash Flow	N/A	N/A	-$7.7M+38.2%	-$12.5M+15.4%	-$14.8M+8.1%	-$16.1M
Investing Cash Flow	N/A	$59K-90.6%	$625K-74.4%	$2.4M-85.2%	$16.5M+796.1%	$1.8M
Financing Cash Flow	$4.4M	N/A	$4.1M-38.2%	$6.6M+138.3%	$2.8M-77.6%	$12.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q2'24	Q4'23	Q2'23
Operating Cash Flow	-$536K-10.6%	-$484K	N/A	$120K+519.9%	-$28K	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	$0	$0	N/A	N/A	N/A
Financing Cash Flow	$1.7M	$0	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NIKI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	2.5%-3.7pp	6.2%+0.9pp	5.3%	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	-654.8%+101.4pp	-756.2%+868.4pp	-1624.6%	N/A
Return on Equity	-5.9%+14.3pp	-20.2%-8.8pp	-11.4%+51.0pp	-62.4%+43.7pp	-106.1%-117.9pp	11.8%
Return on Assets	-7.3%+19.2pp	-26.5%-12.8pp	-13.7%+33.3pp	-47.0%+67.4pp	-114.3%-125.5pp	11.1%
Current Ratio	0.78+0.6	0.22-1.0	1.18	N/A	2.90-5.8	8.70
Debt-to-Equity	N/A	N/A	N/A	0.010.0	0.010.0	0.01
FCF Margin	N/A	N/A	-1791.3%-826.3pp	-965.0%-6.2pp	-958.9%	N/A

Metric	Q4'25	Q3'25	Q2'25	Q4'24	Q3'24	Q2'24	Q4'23	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	0.78+0.2	0.56-2.4	2.98+2.8	0.22	N/A	1.17-0.0	1.18-0.1	1.32
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Is NIKI BIOSOLUTIONS INC, profitable?

No, NIKI BIOSOLUTIONS INC, (NIKI) reported a net income of -$1.4M in fiscal year 2025.

What is NIKI BIOSOLUTIONS INC,'s return on equity (ROE)?

NIKI BIOSOLUTIONS INC, (NIKI) has a return on equity of -5.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is NIKI BIOSOLUTIONS INC,'s operating cash flow?

NIKI BIOSOLUTIONS INC, (NIKI) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are NIKI BIOSOLUTIONS INC,'s total assets?

NIKI BIOSOLUTIONS INC, (NIKI) had $18.7M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does NIKI BIOSOLUTIONS INC, spend on research and development?

NIKI BIOSOLUTIONS INC, (NIKI) invested $353K in research and development during fiscal year 2025.

What is NIKI BIOSOLUTIONS INC,'s current ratio?

NIKI BIOSOLUTIONS INC, (NIKI) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is NIKI BIOSOLUTIONS INC,'s return on assets (ROA)?

NIKI BIOSOLUTIONS INC, (NIKI) had a return on assets of -7.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is NIKI BIOSOLUTIONS INC,'s cash runway?

Based on fiscal year 2025 data, NIKI BIOSOLUTIONS INC, (NIKI) had $3.5M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NIKI BIOSOLUTIONS INC,'s Piotroski F-Score?

NIKI BIOSOLUTIONS INC, (NIKI) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NIKI BIOSOLUTIONS INC,'s earnings high quality?

NIKI BIOSOLUTIONS INC, (NIKI) has an earnings quality ratio of 1.35x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.